68 related articles for article (PubMed ID: 1665589)
21. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
[TBL] [Abstract][Full Text] [Related]
22. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
23. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
Lee YC; McCrystal MR; Christmas TI
N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
[TBL] [Abstract][Full Text] [Related]
25. The fibrinogenolytic activity of purified tryptase from human lung mast cells.
Schwartz LB; Bradford TR; Littman BH; Wintroub BU
J Immunol; 1985 Oct; 135(4):2762-7. PubMed ID: 3161948
[TBL] [Abstract][Full Text] [Related]
26. Fibrinogen degradation products in patients with the Quebec platelet disorder.
Hayward CP; Welch B; Bouchard M; Zheng S; Rivard GE
Br J Haematol; 1997 May; 97(2):497-503. PubMed ID: 9163623
[TBL] [Abstract][Full Text] [Related]
27. [Plasmin-alpha 2-antiplasmin complexes in blood of patient with lichen planus against the background of other fibrinolysis parameters].
Wankiewicz A; Iwan-Zietek I; Kotschy M; Zwolska A
Pol Merkur Lekarski; 2003 Jul; 15(85):72-4. PubMed ID: 14593965
[TBL] [Abstract][Full Text] [Related]
28. [D-dimer and plasminogen activator of the urokinase type: personal experiences with breast cancer].
Neises M; Schäfer T; Strittmatter HJ; Wischnik A; Dettmar P; Melchert F
Geburtshilfe Frauenheilkd; 1993 Jul; 53(7):455-60. PubMed ID: 8370485
[TBL] [Abstract][Full Text] [Related]
29. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
30. Blood coagulation and fibrinolysis in patients with carcinoma of the lung.
Brugarolas A; Elias EG; Takita H; Mink IB; Mittelman A; Ambrus JL
J Med; 1973; 4(2):96-105. PubMed ID: 4127138
[No Abstract] [Full Text] [Related]
31. In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer.
McCulloch P; Douglas J; Lowe GD; Murray G; George WD
Thromb Haemost; 1989 Apr; 61(2):318-21. PubMed ID: 2749603
[TBL] [Abstract][Full Text] [Related]
32. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
Cancer; 1990 Feb; 65(3):481-5. PubMed ID: 2153429
[TBL] [Abstract][Full Text] [Related]
33. Plasma calcitonin as a marker of disease activity in patients with small cell carcinoma of the lung.
Wallach SR; Royston I; Taetle R; Wohl H; Deftos LJ
J Clin Endocrinol Metab; 1981 Sep; 53(3):602-6. PubMed ID: 6267098
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of Veterans Affairs Cooperative Study 188.
Meehan KR; Zacharski LR; Moritz TE; Rickles FR
Am J Hematol; 1995 Jun; 49(2):143-8. PubMed ID: 7771466
[TBL] [Abstract][Full Text] [Related]
35. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients.
Yamaguchi T; Yamamoto Y; Yokota S; Nakagawa M; Ito M; Ogura T
Jpn J Clin Oncol; 1998 Dec; 28(12):740-4. PubMed ID: 9879291
[TBL] [Abstract][Full Text] [Related]
36. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction.
Lee LV; Ewald GA; McKenzie CR; Eisenberg PR
Arterioscler Thromb Vasc Biol; 1997 Apr; 17(4):628-33. PubMed ID: 9108774
[TBL] [Abstract][Full Text] [Related]
37. Fibrinolysis in Dogs with Intracavitary Effusion: A Review.
Zoia A; Drigo M; Caldin M; Simioni P; Piek CJ
Animals (Basel); 2022 Sep; 12(19):. PubMed ID: 36230236
[TBL] [Abstract][Full Text] [Related]
38. Serum concentration of D-dimers as a marker of the activation of the fibrinolytic system in patients undergoing bronchoscopic and thoracoscopic investigations.
Schreiber J; Knolle J; Lüdicke R; Florschütz G; Rosahl W
Respiration; 2003; 70(2):161-5. PubMed ID: 12740513
[TBL] [Abstract][Full Text] [Related]
39. Human neurophysins as potential tumor markers for small cell carcinoma of the lung: application of specific radioimmunoassays.
North WG; Maurer LH; Valtin H; O'Donnell JF
J Clin Endocrinol Metab; 1980 Oct; 51(4):892-6. PubMed ID: 6252226
[TBL] [Abstract][Full Text] [Related]
40. [Fibrinolytic activity of blood and urine in young children with acute pneumonia].
Mamatkulov KhM; Abdullaeva MN
Pediatriia; 1981; (8):14-6. PubMed ID: 7290832
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
